News & Updates

Patients with primary cutaneous B-cell lymphoma (PCBCL) treated with ultra-low dose external beam radiation therapy (EBRT) to 4 Gy total dose in two fractions experience durable local control without skin toxicity, reports a study.

According to patient-reported outcomes (PROs) from the TROPiCS-02 study, sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) chemotherapy is associated with health-related quality of life (HRQoL) benefits across most symptoms and functioning domains among patients with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).

Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.

Higher consumption of raw cruciferous vegetables appears to reduce the risk of recurrence in nonmuscle-invasive bladder cancer (NMIBC) patients treated with induction bacillus Calmette-Guérin (BCG), suggests a study.

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.